A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia

International Clinical Psychopharmacology
Ali DorukAytekin Ozşahin


The focus of this study was the systematic evaluation of the clinical effects of the extract of ginkgo biloba (EGb) as an adjunct to the atypical antipsychotic clozapine in the treatment of refractory schizophrenia. In a placebo-controlled study, 42 patients with chronic, treatment-resistant schizophrenia, who were maintained on optimal doses of clozapine, were administered either 120 mg/day of EGb (N=20) or placebo (N=22) for 12 weeks. Clinical evaluations with the Brief Psychiatric Rating Scale, the Scale for the Assessment of Positive Symptoms, and the Scale for the Assessment of Negative Symptoms were completed biweekly. The use of EGb as an adjunct to clozapine was effective in decreasing negative symptoms, but not positive and overall psychopathology symptoms. EGb produced a mean 7.9+/-7.0 point reduction in the total Scale for the Assessment of Negative Symptoms score compared with a mean 1.8+/-3.5 point reduction in the placebo group (P=0.034). These preliminary data suggested that EGb was found useful for enhancing the effect of clozapine on negative symptoms in patients with treatment-resistant schizophrenia.


Aug 15, 1991·Biological Psychiatry·R ReddyJ N Murthy
Jan 1, 1986·Schizophrenia Bulletin·J B Harrod
Feb 1, 1981·International Journal of Oral Surgery·J O Andreasen
Jan 1, 1994·Neuroscience and Biobehavioral Reviews·J L Cadet, L A Kahler
May 26, 1995·Biochemical Pharmacology·I MaitraL Packer
Oct 1, 1994·Schizophrenia Research·D F HorrobinK Vaddadi
Mar 1, 1996·Schizophrenia Research·S P Mahadik, S Mukherjee
Jan 1, 1998·Transplantation Proceedings·M R First
May 24, 2001·Progress in Neuro-psychopharmacology & Biological Psychiatry·S P MahadikH Lal
Apr 30, 2002·Cell Biochemistry and Function·Murat KulogluNadire Cinkilinc
Sep 6, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Zahoor Ahmad ShahS B Vohora
May 4, 2004·The Journal of Clinical Psychiatry·Jean-Pierre LindenmayerMiranda Chakos
May 25, 2004·Neuropsychobiology·Ganesh DakhaleAvinash Turankar
Feb 8, 2005·Irish Journal of Medical Science·J LyneW T O'Connor


Jan 7, 2010·Current Opinion in Psychiatry·Mathias ZinkAndreas Meyer-Lindenberg
Jun 20, 2013·Evidence-based Complementary and Alternative Medicine : ECAM·Natascia BrondinoPierluigi Politi
Jun 20, 2012·The European Journal of Neuroscience·Patricio O'Donnell
Jun 21, 2014·Neuroscience and Biobehavioral Reviews·Błażej MisiakAndrzej Kiejna
Sep 25, 2009·The International Journal of Neuropsychopharmacology·Vidhi SinghKelvin Chan
Feb 6, 2016·The Cochrane Database of Systematic Reviews·Pedro V S MagalhãesFlávio Kapczinski
Jan 18, 2018·BMC Complementary and Alternative Medicine·Seung Sun RhoWon-Myong Bahk
Mar 20, 2019·The Cochrane Database of Systematic Reviews·Diarmid Jm SinclairClive E Adams
May 10, 2013·Harvard Review of Psychiatry·David N OsserTheo Manschreck
Jun 8, 2013·The Cochrane Database of Systematic Reviews·Saskia P A NicolaïJoep A W Teijink
May 8, 2018·The Australian and New Zealand Journal of Psychiatry·Dan SiskindSteve Kisely
Feb 9, 2021·Oxidative Medicine and Cellular Longevity·Evgeny A ErmakovLiudmila P Smirnova

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here